PATENT CLAIM ANALYSIS

Application Number: 16116036
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["435", "326000"]

Abstract:
The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.

Claim (Index 114):
The method of  claim 105 , wherein the modified immunoglobulin molecule is an antibody fragment.

Metadata:
- Claim Count in Document: 109.0
- Percentile: 96.0
- Lexical Diversity: 2.01923
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15401543', '13625417', '14476582', '15163301', '13229006']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7892645273609266
- 35 USC 102 Novelty (BERT): 0.6660142436990061
- Combined Prediction Score: 0.7769394989947345
- Mean Citation Score: 871.497
- Max Citation Score: 983.8479
- Similarity Product: 635.9699892581998

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test